Joint statement from ATAGI and THANZ on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of COVID-19 Vaccine AstraZeneca

TTS, also known as vaccine induced thrombotic thrombocytopenia (VITT), is a rare newly identified condition with a different mechanism to other causes of thrombosis. Among case reports, there are no known markers for increased risk for TTS/VITT.

The risk of TTS is not likely to be increased in people with the following conditions, and people in these groups can receive COVID-19 Vaccine AstraZeneca:

  • History of blood clots in typical sites
  • Increased clotting tendency that is not immune mediated
  • Family history of blood clots
  • History of ischaemic heart disease or stroke
  • Current or past thrombocytopenia (low platelet count)
  • Those receiving anticoagulation therapy

Read more from the Joint Statement

Read cover letter from Prof Alison McMillian